Thetis Pharmaceuticals Email Format

Biotechnology ResearchConnecticut, United States2-10 Employees

Thetis Pharmaceuticals is a biotechnology research company based in Essex, Connecticut, focused on developing medicines derived from naturally occurring signaling molecules that promote immune homeostasis. Its lead candidate, TP-317, is an oral drug based on Resolvin E1 that targets the BLT1 receptor to modulate innate and adaptive immune responses. The program aims to address inflammatory bowel disease—including ulcerative colitis and Crohn's disease—and solid tumor cancers, conditions with high unmet medical need. The work centers on translating resolvin biology into therapies that support balanced immune function.

It operates with a small team and is positioned as a clinical-stage enterprise pursuing this pathway. In October 2025, Thetis announced the appointment of David N. Cook, PhD, to its Board of Managers and Scientific Advisory Board, signaling governance and scientific oversight as TP-317 progresses toward clinical development.

Sign up for free to view info

Company overview Employee directory